POS0794 INCIDENCE AND PHENOTYPE OF ANTIPHOSPHOLIPID SYNDROME (APS) AFTER PREECLAMPSIA

Background: Obstetric Antiphospholipid syndrom (oAPS) is induced by antiphospholipid antibodies (aPL) and associated with specific pregnancy complications. oAPS requires the combination of at least one obstetrical laboratory criteria (in 2 or more occasions 12 weeks apart). Multiple aPL positivity, lupus anticoagulant (LA) persistently high titers defined as risk profile. “Non-criteria” are cases not fulfilling clinical criteria. Objectives: To investigate incidence after preeclampsia association phenotypes outcome. Methods: The present retrospective cohort analysis included women followed up preeclampsia. Anti-PL (LA, aCL, anti-β2GBI IgG IgM isotype) assessed 8 to PE if positive, again apart. According ISSHP classified severe blood pressure exceeds 160/110mmHg, HELLP syndrome, eclampsia. FGR estimated fetal weight <5 th , birth <10 percentile, and/or pathologic Doppler. Results: Complete data were available for 99 over a period 6 years. 38.4% delivered <34 + 0 weeks. was in 63.6% cases, 58.9%. syndrome diagnosed 34.3% 4 it isolated. prevalence 35 (35.4%) first evaluation, 23 (23.2%) still positive 14/99 (14.1%) fulfilled definition classical oAPS, 9/99 (9.1%) >34 (“non-criteria oAPS”). Of interest, incidende og profiles similar both groups (64.3% vs. 77.8%; p=NS). higher presence APS (APS: 9/23 [39.1%] 21/76 [27.6%]; 3 out isolated profiles. Overall, aCL dominant aPL. 32/35 (91.4%) 22/23 (95.7%) had second investigation, respectively (p=NS). An titer >32.8CU assessment yield LR 10 persistent sensitivity specificity 91.3% 90.9%, respectively. Conclusion: Classical “non-criteria” show pattern distribution regardless gestational age delivery. antibody highly predictive persistence follow up. may be an additional feature particular form. However, studies necessary explore this possible association. References: [1]Tektonidou MG et al, EULAR recommendations management adults Ann Rheum Dis. 2019 Oct;78(10):1296-1304. doi: 10.1136/annrheumdis-2019-215213. Epub May 15. Disclosure Interests: None declared